BioSpace News Archive

Magno-Humphries Laboratories, Inc., is voluntarily recalling one lot of Basic Drugs Brand of Senna Laxative tablets, 8.6mg Sennosides to the consumer level due to a customer complaint that their bottle labeled as Senna Laxative actually contained Basic Drugs Brand of Naproxen Sodium 220mg.

An analysis of patients with newly diagnosed, locally advanced pancreatic cancer treated with up to 6 cycles of ABRAXANE + gemcitabine as an investigational induction therapy (n=106) found that patients had a median time to treatment failure (TTF) of 8.8 months (90% CI: 6.67-9.82), which exceeded the protocol-specified target of 6.6 months (primary endpoint).

The offering is expected to close on January 23, 2018, subject to customary closing conditions.

The publication complements previously published safety analyses and reports efficacy analyses that characterize bardoxolone’s longer-term effects on kidney function.

There are more than 900 regenerative medicine trials underway globally, including trials in cell and gene therapy, a 19 percent increase since 2016

On January 16, 2018, TiGenix received a transparency notification from JPMorgan Chase & Co., following the disposal of voting securities or voting rights on January 9, 2018.

The Company today confirms that it has purchased $25,000 worth of crypto currency Groestlcoin and owns a total of 13,033.8579 GRS Units.

The Company’s common stock will begin trading on The Nasdaq Capital Market effective with the open of business today, January 19, 2018.

The data was presented at the 2018 ASCO Gastrointestinal Cancers Symposium in San Francisco, Calif. today.

The results were published in the January/February issue of the JWOCN, the peer-reviewed publication of the Wound, Ostomy and Continence Nurses Society.